Almirall To Put More Skin In The Game With Derma Buys
The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.
You may also be interested in...
Buying Allergan's US dermatology portfolio will expand the Spanish group's platform in the world's largest dermatology market.
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.
FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.